Clinical Study
Eye (2007) 21, 453–458. doi:10.1038/sj.eye.6702243; published online 17 March 2006
24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension
This clinical study received no financial support from any public or private organization. No author had any proprietary interest in the products mentioned in this study.
It has been presented as a poster in 'World Glaucoma Congress' in Vienna, Austria, 6–9 July 2005.
- 1Department of Ophthalmology, Fatih University Medical School, Ankara, Turkey
- 2Department of Ophthalmology, Inonu University Medical School, Malatya, Turkey
Correspondence: IF Hepsen, Department of Ophthalmology, Fatih University Medical School, A. Turkes Cd. No: 57, 06510 Emek, Ankara, Turkey. Tel: +312 212 6262 1123; Fax: +312 221 3276. E-mail: hepsenif@hotmail.com
Received 21 August 2005; Accepted 29 November 2005; Published online 17 March 2006.
Abstract
Purpose
To compare the 24-h IOP reductions induced by latanoprost, travoprost, and bimatoprost in eyes with exfoliation syndrome (XFS) associated with ocular hypertension (OH).
Methods
This was a prospective, randomized, single masked, and parallel design study with 15 patients in each treatment group. After washout of any previous medications, each patient underwent a baseline 24-h IOP curve testing at 0600, 0900, 1200, 1500, 1800, 2100, and at 2400 (midnight) hours. Patients were then randomized to receive latanoprost, travoprost, or bimatoprost once a day for 3 months. The 24-h curve testing was repeated at first week, and first and third months.
Results
Maximal and minimal IOP was recorded at 0600 and 1800–2100 hours. There was no significant difference among treatment groups at any time-point except for the first week. At the first week, the travoprost group had significantly lower IOP levels than the latanoprost and bimatoprost groups. All medicines significantly lowered 24-h IOP from baseline (P=0.001 for each). Although there was no significant difference in IOP reduction among groups at first week and first month, bimatoprost reduced the 24-h IOP (7.9
1.4) more than travoprost (6.60.5) at the end of the third month (P=0.003). The mean 24-h range of IOP was lowest with travoprost in all visits, and between-group differences was significant for travoprost vslatanoprost (P=0.007) and travoprost vsbimatoprost (P=0.001) at the third month.
Conclusion
Latanoprost, travoprost, and bimatoprost were effective in reducing the 24-h IOP in patients with XFS and OH, and more research is required with a larger study.
Keywords:
exfoliation syndrome, 24-h IOP, latanoprost, travoprost, bimatoprost
